Navigation Links
Dr. John Mendlein Joins aTyr Pharma as Executive Chairman
Date:5/25/2010

tential of the new biology being elucidated with aminoacyl tRNA synthetase resectins."

Dr. Mendlein added, "The genomics efforts missed an important class of extracellular signaling proteins, resectins, which where hiding in the genes of aminoacyl tRNA synthetases, one of the most ancient and biochemically best understood enzyme families in biology. Thanks to aTyr and Dr. Schimmel a new fundamental biology related to intra- and inter-tissue extracellular communication in human physiology hereto unrecognized in medicine is rising up from these ancient, intracellular enzymes. Drug hunting doesn't get any more exciting than new therapeutic intervention points across multiple diseases."

Currently Chairman of Fate Therapeutics and Alevium Pharmaceuticals, Dr. Mendlein has extensive experience shepherding small molecules and biologics from discovery to humans and in building strong, entrepreneurial teams. Previously he was CEO of Adnexus Therapeutics, the leader in the development of a new class of targeted biologics (acquired by Bristol Myers Squibb, BMY). He has served in a variety of senior executive and board roles at both Aurora Biosciences (acquired by Vertex, VRTX) and Affinium Pharmaceuticals; and was a scientist at Smith Kline and French. He has been co-inventor or author of more than 40 issued patents and publications. In various board and executive roles he has been involved with biotech transactions totally over $3.5B in deal value. He received his Ph. D. from the University of California, Los Angeles and his J.D. from the University of California, Hastings.  

About aTyr Pharma

aTyr Pharma engages in the generation of innovative therapeutics based on a new class of naturally occurring human proteins. These proteins, called
'/>"/>

SOURCE aTyr Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team
2. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
3. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
4. Hank Plain Joins Morgenthaler Ventures as Partner
5. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
6. Senior Research Analyst Richard Evans Joins AVOS Life Sciences
7. Dan Broderick Joins Prolog Ventures as Partner
8. Ingenuity Systems Joins Biomarkers Consortium
9. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
10. Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique
11. Progeniq Joins Microsoft in Bio IT Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Decision Resources Group finds that the ... Russia , India and ... in 2013, roughly equal to the size of the ... BRIC market will experience much faster growth as a result of ... Other key findings from Decision Resources Group,s coverage of ...
(Date:8/20/2014)... nerves in your ear could improve the health of ... the University of Leeds used a standard TENS machine ... electrical pulses to the tragus, the small raised flap ... of the ear canal. , The stimulation changed the ... reducing the nervous signals that can drive failing hearts ...
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets  has announced ... Global Strategic Business Report" report to their offering. ... Culture Supplies in US$ Thousands by the following Product Segments: Media, ... for the US, Canada , Japan ... , and Latin America . Annual estimates and ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership with ... from bioactive small molecules. Based on an ... convenient and timely assessment of critical metabolite and ... of Commercial Operations, Christian Darabant, “the value of ... be measured directly by comparison with the approximate ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3'Tickling' your ear could be good for your heart 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... Calif., Nov. 3 Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... results for the third quarter ended September 30, 2009, and ... we reached the 320th event target in our pivotal Phase ... of small cell lung cancer. This event allowed us ...
... ... consulting firm Full Spectrum Software announces key hire. Cindy Larkin has been hired ... software experience to her new role. , ... Southborough, MA (Vocus) November 3, 2009 -- Leading medical device ...
... , - Follow-On Results from ... Demonstrate Efficacy of Nimotuzumab Without Severe, Class-Associated, ... YM BioSciences Inc. (NYSE Amex: YMI ; TSX: YM), ... a diverse portfolio of promising cancer-related products at various stages ...
Cached Biology Technology:Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 7Medical Device Software Engineering Firm Full Spectrum Software Appoints Cindy Larkin to Director of Client Services 2YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009 2YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009 3YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009 4YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009 5
(Date:8/20/2014)... DENVER (August 20, 2014) Women who are poor ... to infants with elevated levels of the stress hormone, ... later in life, according to a new research from ... online recently in the American Journal of Human ... infants and relate it directly to the socioeconomic status ...
(Date:8/20/2014)... YORK and POINT ROBERTS, Washington ... Biometrics Play a Key Role in Addressing Security Concerns in ... ), a global news source covering leading sectors including biometrics, ... wallet market. Jason Peaslee , Managing Partner ... Institute and Gino Pereira , CEO of NXT-ID, Inc. ...
(Date:8/19/2014)... German . ... a large amount of electricity is to be produced with ... to be stored during productive periods so that these fluctuations ... from adequate for the purpose. Science and industry are therefore ... battery systems that used to be too expensive or unsophisticated ...
Breaking Biology News(10 mins):CU Denver researcher shows economic disparities impact infant health 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... The brain may interpret the information it receives from ... previously thought, according to new research from the National ... By studying how monkeys perceive a vibrating object when ... an animal's attention over time influence how a sensory ...
... by researchers at the University of Illinois at Urbana-Champaign indicates ... deep ocean will change with climate change. , The direct ... suggested as one method to help control rising carbon dioxide ... warming. But, because the atmosphere interacts with the oceans, the ...
... have for the first time used gene therapy to ... in an animal model that is genetically susceptible to ... edition of the journal Circulation, the authors say that ... therapeutic gene throughout the body. , "Previous attempts at ...
Cached Biology News:Cracking the perception code 2Cracking the perception code 3How 'Dirt' Could Educate The Immune System And Help Treat Asthma 2Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy 2Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy 3Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy 4
Agarose, Biotechnology grade, 500g...
... UltraMount Plus is formulated for covering tissue sections ... alcohol soluble OR alcohol insoluble end products. ... such as Fast Red or AEC that require ... not, such as DAB. No heating is required ...
... (IC) Fixation Buffer, used in conjunction ... 00-8333), can be used to fix ... intracellular staining of cytokines and other ... have been specially formulated for reducing ...
Cytofix Buffer 100 mls...
Biology Products: